CytomX Therapeutics (CTMX) Research & Development (2014 - 2026)

CytomX Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $19.2 million for Q1 2026.

• Quarterly Research & Development rose 1.96% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (down 13.84% YoY) and the FY2025 annual result came in at $68.7 million, down 17.57% from the prior year.
• Research & Development was $19.2 million for Q1 2026 at CytomX Therapeutics, down from $21.2 million in the prior quarter.
• Across five years, Research & Development topped out at $31.2 million in Q2 2022 and bottomed at $13.3 million in Q2 2025.
• A 5-year average of $21.2 million and a median of $20.7 million in 2023 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 43.58% in 2025, while the deepest fall reached 47.08% in 2025.
• CytomX Therapeutics' Research & Development stood at $19.6 million in 2022, then retreated by 0.91% to $19.4 million in 2023, then slipped by 23.71% to $14.8 million in 2024, then jumped by 43.58% to $21.2 million in 2025, then slipped by 9.4% to $19.2 million in 2026.
• Business Quant data shows CTMX's Research & Development at $19.2 million in Q1 2026, $21.2 million in Q4 2025, and $15.3 million in Q3 2025.